EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluating the Combined Effect of a Choline Kinase Inhibitor and Temozolomide Therapy in a Mouse Model of Glioblastoma Using 1 H MR Spectroscopy and IVIM‐DWI

Tareq Alrashidi, Sourav Bhaduri, Elisabeth Non Gash, Mohesh Moothanchery, Christopher Ball, Mahon L Maguire, Lorenzo Ressel, Harish Poptani

NMR in Biomedicine · 2025-09 · 38 (9)

DOI: 10.1002/nbm.70113 ↗

Kurz gefasst

Fachartikel in der Zeitschrift NMR in Biomedicine, online erschienen am 04.08.2025. Verfasst von Tareq Alrashidi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Centre for PreClinical Imaging, University of Liverpool, Liverpool, UK. Hauptthemen laut MEDLINE: Glioblastoma, Choline Kinase, Diffusion Magnetic Resonance Imaging, Proton Magnetic Resonance Spectroscopy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Education, Kingdom of Saudi Arabia, Isle of Man Anti-Cancer Research Charity.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study evaluated the therapeutic efficacy of combining a choline kinase alpha (ChoK α ) inhibitor, MN58b, and temozolomide (TMZ) in a syngeneic GL261 glioblastoma (GBM) mouse model. It used MR spectroscopy (MRS) and intravoxel incoherent motion diffusion‐weighted imaging (IVIM‐DWI) to assess metabolic and microstructural changes within the tumor. Fifty‐two C57BL/6 mice had GL261 cells implanted intracranially and were divided into four groups: saline control, MN58b, TMZ, and MN58b + TMZ ( n = 16, 14, 11, and 11, respectively). Treatments were administered for 5 days, starting 10 days post‐implantation. MRI scans (T 2 ‐weighted, MRS, IVIM‐DWI) were performed at baseline, during treatment (Day 3), and post‐treatment (Day 6). The histological analysis evaluated the tumor mitotic index and caspase‐3 expression. Combination therapy with MN58b + TMZ significantly reduced tCho/NAA, Lip + Lac/tCr, and mI/tCr, suggesting decreased phosphocholine synthesis and tumor proliferation. IVIM‐DWI showed a significant increase in diffusion coefficient (D) values, indicating reduced cell density. Metabolic changes detected by 1 H MRS were observable as early as Day 3 post‐treatment initiation, preceding microstructural alterations detected by IVIM‐DWI at Day 6. This suggests that MRS biomarkers may serve as early indicators of treatment response, facilitating timely therapeutic decisions. Histology confirmed a significantly lower mitotic index relative to control tumors in the combination treatment group. Significantly prolonged survival with combination therapy was noted relative to other groups. However, the tumor volumes were not significantly different between groups. Combination therapy targeting ChoK α and cellular proliferation with MN58b and TMZ outperformed individual treatments for GBM, warranting further exploration. The integration of MN58b with the current standard of care (TMZ + RT) might further enhance the therapeutic outcomes. MRS and IVIM‐DWI demonstrate potential utility as non‐invasive imaging markers for treatment monitoring.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaCholine KinaseDiffusion Magnetic Resonance ImagingProton Magnetic Resonance SpectroscopyBrain NeoplasmsDacarbazineAnimalsTemozolomideMice, Inbred C57BLDisease Models, AnimalCell Line, TumorMice

Stichwörter der Autor:innen

GBMIVIMMR spectroscopycancerglioblastomamicrostructuretreatment response

Substanzen

TemozolomideCholine KinaseDacarbazine

Autor:innen und Institutionen

  • Centre for PreClinical Imaging, University of Liverpool, Liverpool, UK.
  • Institute for Advancing Intelligence (IAI), TCG CREST, Kolkata, India.
  • Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India.
  • Department of Veterinary Anatomy Physiology and Pathology, University of Liverpool, Chester, UK.

Förderung

  • Ministry of Education, Kingdom of Saudi Arabia
  • Isle of Man Anti-Cancer Research Charity

Zitieren

APA

Alrashidi, T., Bhaduri, S., Gash, E. N., Moothanchery, M., Ball, C., Maguire, M. L., Ressel, L., & Poptani, H. (2025). Evaluating the Combined Effect of a Choline Kinase Inhibitor and Temozolomide Therapy in a Mouse Model of Glioblastoma Using 1 H MR Spectroscopy and IVIM‐DWI. NMR in Biomedicine, 38(9). https://doi.org/10.1002/nbm.70113

Vancouver

Alrashidi T, Bhaduri S, Gash EN, Moothanchery M, Ball C, Maguire ML, et al. Evaluating the Combined Effect of a Choline Kinase Inhibitor and Temozolomide Therapy in a Mouse Model of Glioblastoma Using 1 H MR Spectroscopy and IVIM‐DWI. NMR in Biomedicine. 2025;38(9). doi:10.1002/nbm.70113

BibTeX
@article{Alrashidi2025,
  author = {Alrashidi, Tareq and Bhaduri, Sourav and Gash, Elisabeth Non and Moothanchery, Mohesh and Ball, Christopher and Maguire, Mahon L and Ressel, Lorenzo and Poptani, Harish},
  title = {Evaluating the Combined Effect of a Choline Kinase Inhibitor and Temozolomide Therapy in a Mouse Model of Glioblastoma Using 1 H MR Spectroscopy and IVIM‐DWI},
  journal = {NMR in Biomedicine},
  year = {2025},
  volume = {38},
  number = {9},
  doi = {10.1002/nbm.70113}
}
Kostenlos starten →